There are currently 261 ongoing clinical trials involving Sleep Disorders
Of the 261 trials,104 trials are in Phase II
Furthermore, 67 trials are in Phase IV
The global pharmaceutical industry is steadily developing new drugs for Sleep Disorders, a Central Nervous System indication. The largest number of ongoing clinical trials for Sleep Disorders is conducted in the Asia-Pacific region. North America and Europe are among some of the other prominent regions engaged in Sleep Disorders-related drug trials.
Jazz Pharmaceuticals Plc: The leading ongoing Sleep Disorders related clinical trial sponsor
Jazz Pharmaceuticals Plc is the top sponsor for Sleep Disorders-related ongoing clinical trials.
Vanda Pharmaceuticals Inc, Massachusetts General Hospital, VA Office of Research and Development, Johnson & Johnson, and Yangtze River Pharmaceutical Group are among other notable clinical trial sponsors involved in Sleep Disorders. A clinical trial sponsor can be a Company, Government, Individual, or Institution.
Marketed Drugs involving Sleep Disorders
Sodium oxybate (Xyrem), Suvorexant (Belsomra/ Silumbra), and Tasimelteon (Hetlioz, Hetlioz LQ, and VEC-162) are key marketed drugs involving Sleep Disorders.
Sodium oxybate (Xyrem) is a sodium salt of gamma-hydroxybutyrate, acts as a central nervous system depressant. It functions via Gamma-Aminobutyric Acid Type B Receptor Subunit (Gamma-Aminobutyric Acid (GABA) B Receptor or GABBR) Agonist mechanism of action. It is formulated as solution for oral route of administration. Xyrem is indicated for the treatment of cataplexy in narcolepsy and for the treatment of excessive daytime sleepiness (EDS) in narcolepsy. Sodium oxybate was first approved in 2002 and is marketed globally including in the US, the UK, France, and Germany by Jazz Pharmaceuticals Inc.
Suvorexant (Belsomra/ Silumbra) is a dual orexin receptor antagonist. It functions via the Orexin Receptor Type 1 Antagonist, Orexin Receptor Type 2 Antagonist mechanism of action. It is formulated as film-coated tablets and tablets for oral route of administration. It is indicated in the treatment of insomnia characterized by difficulties with sleep onset and or sleep maintenance. Suvorexant was first approved in 2014 and is marketed globally including in the US, Australia, and Japan by Merck & Co Inc.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer
Contact the team or request a demo to find out how our data can drive your business forward